Retrospective Study
Copyright ©The Author(s) 2023.
World J Gastroenterol. Nov 14, 2023; 29(42): 5716-5727
Published online Nov 14, 2023. doi: 10.3748/wjg.v29.i42.5716
Figure 3
Figure 3 Comparison of the hepatitis C incidence cases with the forecasts under the seasonal autoregressive integrated moving average and seasonal autoregressive fractionally integrated moving average. A: Comparison of the 12-step ahead forecasts under the seasonal autoregressive integrated moving average (SARIMA) and seasonal autoregressive fractionally integrated moving average (SARFIMA); B: Comparison of the 90-step ahead forecasts under the SARIMA and SARFIMA; C: Projection into 2030 under the SARFIMA. The predictive results are plotted in the right of the virtual vertical line. It appeared that the forecasts under the SARFIMA are in closer proximity to the actual hepatitis C incidence values and the predictive hepatitis C incidence cases would begin to recede in the next years. 95%CI: 95% confidence interval; SARFIMA: Seasonal autoregressive fractionally integrated moving average; SARIMA: Seasonal autoregressive integrated moving average.